viewEmerald Clinics Ltd

Emerald Clinics halted with RWE platform news upcoming

The company’s real-world evidence data platform provide insights into the safe and effective use of medicines, to improve patient care, and to identify novel uses of existing or new therapeutics.

Emerald Clinics Ltd - Emerald Clinics in trading halt pending news of RWE platform
The halt will remain until the beginning of trading on Monday, June 22, or when an announcement is released

Emerald Clinics Ltd (ASX:EMD) has been granted a trading halt with news upcoming in regard to its real-world evidence data (RWE) platform.

The trading halt will remain in place until the beginning of regular ASX trading on Monday, June 22, or when an announcement is released to the market, whichever occurs earliest.

EMD securities last traded at 5.6 cents and in the last three months are up from 4 cents at the close on March 23.

National Clinical data platform

In early May, the company was promoted to program manager for the development of a national Clinical Data and Analytics Platform (CDAP) of COVID-19 patient cases.

As part of a partnership between several Australian state health bodies, the Federal Government and universities, the platform aims to collect clinical data from confirmed COVID-19 patients and a variety of sources in real-time.

The data will then be analysed to inform predictive models that can support point-of-care decision making by clinicians across likely disease progression as well as treatment options for each patient.

Additionally, the platform is expected to underpin a series of planned adaptive trials of COVID-19 treatment protocols while allowing for forecasting of likely demand on health services.

Quick facts: Emerald Clinics Ltd

Price: 0.083 AUD

Market: ASX
Market Cap: $17.55 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Emerald Clinics Ltd named herein, including the promotion by the Company of Emerald Clinics Ltd in any Content on the Site, the Company...


Emerald Clinics makes first big move into UK with Spectrum Biomedical deal

Emerald Clinics Ltd (ASX:EMD) CEO Dr Michael Winlo talks to Proactive about his company’s new partnership with Spectrum Biomedical UK to develop a real-world evidence data system in the UK. Shares in the company soared in response to the agreement which will see Emerald design and deliver...

on 11/8/20

2 min read